Tiziana Life Sciences (Nasdaq: TLSA) reported that Executive Chairman and Founder Gabriele Cerrone, via Panetta Partners, purchased 42,357 common shares at $0.99 per share. This increases his holding to 44,814,587 shares, representing 34.93% of the company’s issued share capital.
The company’s lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, is being developed for immunomodulation. According to Tiziana Life Sciences, 14 patients with non-active secondary progressive multiple sclerosis in an expanded access program showed disease improvement or stability within six months. Intranasal foralumab is also being evaluated in a Phase 2a randomized, double-blind, placebo-controlled, dose-ranging trial, and is described by the company as the only fully human anti-CD3 mAb currently in clinical development.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market reaction after executive share purchase: TLSA -5.50% in the Jul 22 session
-5.50%2.0x vol
4 alerts
-5.50%Session close to close
+8.4%Peak Tracked
-14.9%Trough Tracked
$129.17MMarket Cap
2.0xRel. Volume
In the Jul 22 session, TLSA declined 5.50%, reflecting a notable negative market reaction.
Argus tracked a peak move of +8.4% during that session.
Argus tracked a trough of -14.9% from its starting point during tracking.
Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Trading volume was elevated at 2.0x the daily average, suggesting increased selling activity.
The stock moved -5.5% in the session following this news. Historical event 1061247 recorded a -9.32%...
Analysis
The stock moved -5.5% in the session following this news. Historical event 1061247 recorded a -9.32% 24-hour reaction after Phase 2a enrollment news. That divergence shows biotech announcements can trade independently of stated progress; short positioning was categorized as low in the available risk data.
Key Figures
Shares purchased:42,357 common sharesPurchase price:$0.99 per shareTotal holding:44,814,587 common shares+4 more
7 metrics
Shares purchased42,357 common sharesExecutive Chairman purchase
Purchase price$0.99 per shareExecutive Chairman purchase
Total holding44,814,587 common sharesAfter the purchase
Issued share capital34.93%Executive Chairman's total holding
Expanded Access patients14 patientsna-SPMS Expanded Access Program
Improvement or stability period6 monthsObserved in all 14 Expanded Access patients
Trial phasePhase 2aRandomized, double-blind, placebo-controlled study
Expanded Access data showed fatigue improvement and disability stabilization trends.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent news reactions were mixed, including positive reactions to executive share purchases but a -9.32% reaction to Phase 2a enrollment news.
Key Terms
anti-CD3 monoclonal antibody, immunomodulation, expanded access, open-label, +1 more
5 terms
anti-CD3 monoclonal antibodymedical
"intranasal foralumab, a fully human, anti-CD3 monoclonal antibody"
A lab-made antibody engineered to attach to CD3, a protein found on T cells, so it can change how those immune cells behave. Investors care because these drugs can act like a targeted brake on an overactive immune system—useful for autoimmune disease, transplant rejection or as part of cancer therapies—but they also carry clinical trial, safety and regulatory risks that determine commercial success.
Immunomodulation is the intentional changing of the immune system’s activity—either ramping it up, calming it down, or redirecting it—to treat disease or prevent harmful reactions. Think of it like adjusting a thermostat for the body’s defenses: the goal is to achieve the right balance so patients heal without excessive inflammation or infection risk. For investors, immunomodulation matters because therapies in this area can address many diseases, carry regulatory and safety considerations, and often determine commercial potential and clinical risk.
Access that lets patients use an experimental drug or medical device outside of a formal clinical trial when no approved options are available. Think of it like allowing someone to test-drive a prototype car because they have no other transportation; for investors, expanded access can affect short-term demand, provide additional safety or usage information, and carry reputational or regulatory risks that may influence a company’s prospects and potential future sales.
open-labeltechnical
"have been dosed in an open-label intermediate sized Expanded Access"
Open-label describes a situation where everyone involved in a study or process knows the full details, such as who is receiving a treatment or intervention. For investors, understanding whether a project or product is open-label helps gauge the level of transparency and potential biases, influencing trust and decision-making. It’s like knowing whether a test or experiment is conducted openly or behind closed doors.
dose-rangingtechnical
"a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial"
A dose-ranging study is a clinical trial that tests multiple amounts of a drug to find what dose works best and is safest, much like trying different spice levels in a recipe to get the right balance. For investors, results clarify whether a medicine is effective at practical doses, how likely it is to win regulatory approval, what side effects to expect, and how the treatment might be priced and used in the market.
BOSTON, July 22, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that its Executive Chairman and Founder, Mr. Gabriele Cerrone, through Panetta Partners Ltd, an entity in which he has a beneficial interest, has increased his holdings with the purchase of 42,357 common shares at $0.99 per share, bringing his total holding to 44,814,587 common shares, which is 34.93% of issued share capital.
About Foralumab
Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients.In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).
Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.[1],[2]
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative intranasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.
For further inquiries:
Tiziana Life Sciences Ltd Paul Spencer, Business Development, and Investor Relations +44 (0) 207 495 2379 email: info@tizianalifesciences.com
What insider share purchase did Tiziana Life Sciences (NASDAQ: TLSA) announce on July 22, 2026?
Tiziana Life Sciences announced that Executive Chairman Gabriele Cerrone bought 42,357 TLSA common shares at $0.99 per share. According to Tiziana Life Sciences, the purchase was made through Panetta Partners, an entity in which he has a beneficial interest, increasing his overall stake.
How many Tiziana Life Sciences (TLSA) shares does Gabriele Cerrone now own after the July 2026 purchase?
After the transaction, Gabriele Cerrone holds 44,814,587 Tiziana Life Sciences common shares, equal to 34.93% of issued share capital. According to Tiziana Life Sciences, this total reflects his position following the 42,357-share purchase at $0.99 per share through Panetta Partners.
What is intranasal foralumab in Tiziana Life Sciences (TLSA) clinical pipeline?
Intranasal foralumab is Tiziana Life Sciences’ lead development candidate, a fully human anti-CD3 monoclonal antibody for immunomodulation. According to Tiziana Life Sciences, dosing via the nasal route is designed to stimulate regulatory T cells and may support treatment of neuroinflammatory and neurodegenerative diseases, including non-active secondary progressive multiple sclerosis.
What early clinical results has Tiziana Life Sciences reported for intranasal foralumab in non-active SPMS?
Tiziana Life Sciences reports that 14 na-SPMS patients in an open-label expanded access program showed disease improvement or stability within six months. According to Tiziana Life Sciences, all treated patients in this intermediate-sized program received intranasal foralumab under NCT06802328, providing preliminary clinical observations.
What Phase 2a trial is evaluating intranasal foralumab for non-active secondary progressive multiple sclerosis (TLSA)?
Intranasal foralumab is being studied in a Phase 2a randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in non-active secondary progressive multiple sclerosis. According to Tiziana Life Sciences, this study, registered as NCT06292923, is designed to further assess efficacy, safety, and optimal dosing of the candidate.
How does Tiziana Life Sciences describe its intranasal immunotherapy approach to TLSA investors?
Tiziana Life Sciences describes its intranasal technology as a transformational drug delivery platform enabling alternative routes of immunotherapy. According to Tiziana Life Sciences, this approach may improve efficacy, safety, and tolerability versus intravenous delivery and is supported by patents and pending applications covering broader pipeline applications.
